À titre de membre permanent, vous pourrez accéder au contenu éditorial et de formation continue, utiliser le moteur de recherche, recevoir nos newsletters, participer aux discussions, télécharger des diapositives et plus encore.
In a head-to-head comparison, liraglutide reduced A1C levels more effectively with virtually no hypoglycemia and with weight loss, compared with weight gain with glimepiride.
The largest study to date looking at whether the risk of bone fractures is increased in the setting of thiazolidinedione drugs suggests that fracture risk is more than 40% higher in people taking TZDs and that both men and women are vulnerable.
ACCORD's early findings of a link between low A1C level and increased risk of cardiovascular death do not hold up under analysis; the link is not causal.
Carotid artery intima media thickness was 38% lower in subjects taking pioglitazone compared with those taking placebo in the diabetes-prevention trial ACTOS Now.
The investigational glucagonlike peptide-1 receptor agonist exenatide lowers hemoglobin A1C levels to a greater extent; more patients with type 2 diabetes reached A1C targets.
The investigational glucagonlike peptide-1 (GLP-1) analog is also associated with more weight loss and better tolerability than the already-on-the-market GLP-1 receptor blocker exenatide.
Overall rates of major CV events also were no different between revascularization and medical therapy, although CABG alone—but not PCI—was associated with a reduction in the risk of cardiovascular events, particularly nonfatal MI, compared with medical therapy, investigators note.
The trial concluded with the rosiglitazone being "noninferior" to metformin/sulfonylurea therapy with respect to CV death or hospitalization as adverse events over a follow-up of about five years. Researchers and observers disagree sharply, however, over what those results and other findings in the trial mean for diabetes therapy.
